Seeking Alpha

Curis (CRIS +4.8%) grabs some attention from analysts after landing FDA approval for Erivedge....

Curis (CRIS +4.8%) grabs some attention from analysts after landing FDA approval for Erivedge. Oppenheimer raised its rating to Outperform with a new price target of $7.50, while Summer Street reiterated a Buy rating with a $7 PT. Shares have sputtered since the news broke on a bit of buy-the-rumor, sell-the-news trading.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector